Floatz logo

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE

Neuropathy

Gary MorrowSmall moleculePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Neuropathy cohort.

Asset / SponsorPhaseRating
Eloxatin
Tanta University
Phase 3BBB
Amitriptyline
Gary Morrow
Phase 3BB
Carboplatin
Alliance for Clinical Trials in Oncology
Phase 3BB
MAGNESIUM METALLICUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Glutathione
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 20 →

Same molecule, other indications

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:

major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →